MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/noajnl/vdaa168

Медицинская библиотека · Neuro-oncology advances · 2020

Outcome and molecular analysis of young children with choroid plexus carcinoma treated with non-myeloablative therapy: results from the SJYC07 trial.

Liu Anthony P Y, Wu Gang, Orr Brent A, Lin Tong, Ashford Jason M, Bass Johnnie K, Bowers Daniel C, Hassall Tim, Fisher Paul G, Indelicato Daniel J, Klimo Paul, Boop Frederick, Conklin Heather, Onar-Thomas Arzu, Merchant Thomas E, Ellison David W, Gajjar Amar, Robinson Giles W

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Choroid plexus carcinoma (CPC) is a rare and aggressive tumor of infancy without a clear treatment strategy. This study describes the outcomes of children with CPC treated on the multi-institutional phase 2 SJYC07 trial and reports on the significance of clinical and molecular characteristics.

METHODS

Eligible children <3 years-old with CPC were postoperatively stratified to intermediate-risk (IR) stratum if disease was localized or high-risk (HR) stratum, if metastatic. All received high-dose methotrexate-containing induction chemotherapy. IR-stratum patients received focal irradiation as consolidation whereas HR-stratum patients received additional chemotherapy. Consolidation was followed by oral antiangiogenic maintenance regimen. Survival rates and potential prognostic factors were analyzed.

RESULTS

Thirteen patients (median age: 1.41 years, range: 0.21-2.93) were enrolled; 5 IR, 8 HR. Gross-total resection or near-total resection was achieved in ten patients and subtotal resection in 3. Seven patients had TP53-mutant tumors, including 4 who were germline carriers. Five patients experienced progression and died of disease; 8 (including 5 HR) are alive without progression. The 5-year progression-free survival (PFS) and overall survival rates were 61.5 ± 13.5% and 68.4 ± 13.1%. Patients with TP53-wild-type tumors had a 5-year PFS of 100% as compared to 28.6 ± 17.1% for TP53-mutant tumors (P = .012). Extent of resection, metastatic status, and use of radiation therapy were not significantly associated with survival.

CONCLUSIONS

Non-myeloablative high-dose methotrexate-containing therapy with maximal surgical resection resulted in long-term PFS in more than half of patients with CPC. TP53-mutational status was the only significant prognostic variable and should form the basis of risk-stratification in future trials.

Для цитирования: Liu Anthony P Y, Wu Gang, Orr Brent A, Lin Tong, Ashford Jason M, Bass Johnnie K, Bowers Daniel C, Hassall Tim, Fisher Paul G, Indelicato Daniel J, Klimo Paul, Boop Frederick, Conklin Heather, Onar-Thomas Arzu, Merchant Thomas E, Ellison David W, Gajjar Amar, Robinson Giles W. Outcome and molecular analysis of young children with choroid plexus carcinoma treated with non-myeloablative therapy: results from the SJYC07 trial.. Neuro-oncology advances. 2020. DOI: 10.1093/noajnl/vdaa168.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.